Drug
Aav Gad Low Dose
Aav Gad Low Dose: highest development phase Phase 1/2, developed by MeiraGTx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAV-GAD Low Dose NCT05603312 | Phase 1/2 | Parkinson's Disease |
Latest
No recent events.
Follow Aav Gad Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.